Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Health and Drug Alerts

Nefazodone (Serzone) withdrawn because of hepatotoxicity

Stephen Choi
CMAJ November 25, 2003 169 (11) 1187;
Stephen Choi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: Because of concerns of hepatotoxicity, the sale of the antidepressant nefazodone hydrochloride (Serzone) will be discontinued by the manufacturer effective Nov. 27, 2003. Since the drug's introduction in 1994, there have been 51 Canadian reports of adverse hepatic events, including jaundice, hepatitis and hepatocellular necrosis. In 2 of these cases the patients subsequently underwent liver transplantation. Also, an article published earlier this year found an unexpectedly high number of reports of hepatic injury associated with nefazodone in the World Health Organization's database of adverse drug reactions.1

Figure1

Figure.

The drug: Nefazodone is an antidepressant structurally distinct from selective serotonin reuptake inhibitors (SSRIs), tricyclics, tetracyclics and monoamine oxidase inhibitors. It achieves its clinical effects by inhibiting the reuptake of primarily serotonin but also norepinephrine and by antagonizing the postsynaptic 5-HT2 receptor and α1-adrenergic receptors. Nefazodone is metabolized by the cytochrome p450 isoenzyme, CYP 3A4, but it is also an inhibitor of this enzyme, which results in potential interactions with numerous drugs, including HMG–CoA (3-hydroxy-3-methylglutaryl–coenzyme A) reductase inhibitors, carbamazepine and macrolide antibiotics.

What to do: If you have patients who are currently taking nefazodone, then you should switch the treatment to an alternative therapy before Nov. 27, 2003, taking into account the patient's past response to antidepressants, risk of overdose, side effects, drug interactions and cost.2 SSRIs remain the most popular class of antidepressants; however, if your patient has responded well to nefazodone, other drugs are available that have similar mechanisms of action, specifically those inhibiting both serotonin and norepinephrine reuptake.3 Should you choose a monoamine oxidase inhibitor, a washout period of 1 week is recommended after discontinuing nefazodone.

If patients who are taking nefazodone show signs or symptoms of hepatic dysfunction, then the drug should be stopped immediately and the patient investigated for other potential causes. In addition, these patients should be closely followed for progression of hepatic problems. The majority of reported cases of hepatotoxicity associated with nefazodone occurred within the first 4 months of starting the drug. In one report, only 17 (53%) of 32 patients who had nefazodone-induced liver dysfunction recovered without sequelae.4

Stephen Choi Editorial Fellow CMAJ

References

  1. 1.↵
    Spigset O, Hagg S, Bate A. Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 2003;18:157-61.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. CMAJ 2002;167(11):1253-60.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression [published erratum in Lancet 2000;355:2000]. Lancet 2000;355:911-8.
    OpenUrl
  4. 4.↵
    Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002; 47: 375-7.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (11)
CMAJ
Vol. 169, Issue 11
25 Nov 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nefazodone (Serzone) withdrawn because of hepatotoxicity
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Nefazodone (Serzone) withdrawn because of hepatotoxicity
Stephen Choi
CMAJ Nov 2003, 169 (11) 1187;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Nefazodone (Serzone) withdrawn because of hepatotoxicity
Stephen Choi
CMAJ Nov 2003, 169 (11) 1187;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Comparison of the Bioactivation Potential of the Antidepressant and Hepatotoxin Nefazodone with Aripiprazole, a Structural Analog and Marketed Drug
  • BIOACTIVATION OF THE NONTRICYCLIC ANTIDEPRESSANT NEFAZODONE TO A REACTIVE QUINONE-IMINE SPECIES IN HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROME P450 3A4
  • Incomplete patient drug information still a problem
  • Google Scholar

More in this TOC Section

  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
  • Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Drugs: psychotherapeutic
    • Drugs: adverse reactions

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire